Source: TUFTS UNIVERSITY submitted to NRP
THE USE OF STAPHYLOCOCCUS XYLOSUS TO TREAT BOVINE INTRAMAMMARY STAPHYLOCOCCUS AUREUS INFECTIONS
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
COMPLETE
Funding Source
Reporting Frequency
Annual
Accession No.
0192775
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Jul 1, 2002
Project End Date
Jan 31, 2007
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
TUFTS UNIVERSITY
200 WESTBORO ROAD
N. GRAFTON,MA 01536
Performing Department
ENVIRONMENTAL & POPULATION HEALTH
Non Technical Summary
To determine if Staphylococcus xylosus can be used as a therapy for Staphylococcus aureus mastitis
Animal Health Component
100%
Research Effort Categories
Basic
(N/A)
Applied
100%
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3113410110075%
7113450110025%
Goals / Objectives
This is an experiment to test the use of a non-antibiotic alternative for treating Staphylococcus aureus mastitis in dairy cows. The treatment consists of infusing Staphylococcus xylosus bacteria into bovine mammary gland quarters found to be naturally infected with Staphylococcus aureus.
Project Methods
Ten cows will be selected from commercial dairy herds that have S. aureus infections in one quarter based upon direct microscopic somatic cell counts and individual quarter cultures. Five of these cows will be subjected to the experimental protocol and five cows will be used as control animals. Experimental cows will be inoculated into the mammary gland with 1000 to 2000 CFU of S. xylosus at the beginning of the experiment. These cows are to receive no intramammary antibiotics during the course of the experiment. Control cows will not be infused with S. xylosus but may be treated with intramammary antibiotics at the discretion of the cows' owners. All cows will have their milk cultured and a DMSCC performed on days 0, 5, 15, and 30 post-inoculation.

Progress 07/01/02 to 01/31/07

Outputs
No significant differences were observed between treated and control quarters during this experiment for mean somatic cell count, average somatic cell count, and percent of cows infected with Staphylococcus aureus mastitis. There was a trend toward higher infection rates in experimental quarters during the experiment. This trend may have been due to the fact that super-infected quarters, those with more than one bacteria, were less able to cope with infection leading to higher rates of mastitis.

Impacts
This study provides no support for the use of Staphylococcus xylosus to treat Staphylococcus aureus-infected quarters. Experimental cows had higher somatic cell counts and were more likely to be positive for bacteria than were control quarters.

Publications

  • No publications reported this period


Progress 03/01/05 to 06/30/05

Outputs
No significant differences were observed between treated and control quarters during the course of this experiment for the following traits: mean somatic cell count, average somatic cell count, and percent of cows infected with Staphylococcus aureus mastitis. There was a trend toward slightly higher infection rates in treated quarters during weeks 2 and 4. This was not anticipated. This trend may have been due to the fact that super-infecting quarters with more than one bacteria overwhelmed the cows immune systems, increasing the likelihood of maintaining a Staphylococcus aureus infection.

Impacts
See progress report.

Publications

  • No publications reported this period


Progress 07/01/04 to 02/10/05

Outputs
Nine experimental quarters and 10 control quarters were used in this study. Experimental Staphylococcus aureus-infected quarters were infused with Staphylococcus xylosus while control quarters were not. Milk cultures and direct microscopic somatic cell counting was performed on days 0,7,14, and 30 of the study. Results were as follows: Experimental quarters positive for Staphylococcus aureus on days 0,7,14, and 30: 100,90,90,90. Contol quarters positive for Staphylococcus aureus on days 0,7,14,and 30: 100, 90, 70, 80. Average SCC (millions) in experimental quarters on days 0,7,14,and 30: 6.7, 7.8, 5.5, 3.2. Average SCC (millions) in control quarters on days 0,7,14,and 30: 8.1,11.9,7.8,13.6. Mean SCC (millions) in experimental quarters on days 0,7,14, and 30: 6.0,5.0,2.5,3.5. Mean SCC (millions) in control quarters on days 0,7,14,and 30: 6.5,14,9,12.5.

Impacts
The data has not yet been analyzed statistically to determine if there are significant differences. Once statistical analysis is done, an impact statement will be available.

Publications

  • No publications reported this period


Progress 12/31/03 to 06/07/04

Outputs
The experimental cows in this study have been treated and their response to the treatment has been measured. Two control cows have completed the study protocol as well. Eight control cows still remain to be identified and have their milk collected. Once eight more naturally infected S. aureus mastitis cows are identified, milk samples will be collected on days 0, 7,14, and 28 from these cows. The milk collected from these eight cows will be cultured and the somatic cell count will be determined in each sample.

Impacts
If this treatment is successful, it will allow for a non-antibiotic alternative to treat bovine Staphylococcus aureus infections.

Publications

  • No publications reported this period


Progress 01/01/02 to 12/31/02

Outputs
This study is being performed to determine if Staphylococcus xylosus bacteria can be used to treat bovine intramammary Staphylococcus aureus infections. Experimental cows have all been given the experimental treatment and their response to that treatment has been measured. Two of ten control cows have been monitored to compare their response to infection without treatment. Eight more control cows must be located and followed to determine their response to this type of infection.

Impacts
If this treatment is successful, it will allow for a non-antibiotic alternative to treat bovine Staphylococcus aureus infections.

Publications

  • No publications reported this period